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Abstract
Background: Chemoradiotherapy remains the standard of care for locally advanced rectal cancer. Efforts to
intensify treatment and increase response rates have yet to yield practice changing results due to increased toxicity
and/or absence of increased radiosensitization. Enadenotucirev (EnAd) is a tumour selective, oncolytic adenovirus
which can be given intravenously. Pre-clinical evidence of synergy with radiation warrants further clinical testing
and assessment of safety with radiation.
Methods: Eligibility include histology confirmed locally advanced rectal cancer that require chemoradiation. The
trial will use a Time-to-Event Continual Reassessment Model-based (TiTE-CRM) approach using toxicity and efficacy
as co-primary endpoints to recommend the optimal dose and treatment schedule 30 patients will be recruited.
Secondary endpoints include pathological complete response the neoadjuvant rectal score. A translational program
will be based on a mandatory biopsy during the second week of treatment for ‘proof-of-concept’ and exploration
of mechanism. The trial opened to recruitment in July 2019, at an expected rate of 1 per month for up to 4 years.
Discussion: Chemoradiation with Enadenotucirev as a radiosensitiser in locally Advanced Rectal cancer (CEDAR) is a
prospective multicentre study testing a new paradigm in radiosensitization in rectal cancer. The unique ability of
EnAd to selectively infect tumour cells following intravenous delivery is an exciting opportunity with a clear
translational goal. The novel statistical design will make efficient use of both toxicity and efficacy data to inform
subsequent studies.
Trial registration: ClinicalTrial.gov, NCT03916510. Registered 16th April 2019.
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Background
Locally advanced rectal cancer (LARC) is defined by the
presence of T3/4 disease and/or nodal involvement in the
absence of distal metastatic disease. For many years the
standard of care has been a multimodal approach incorp-
orating neoadjuvant long-course chemoradiotherapy
(CRT) with concurrent fluoropyrimidine, followed by total
mesorectal excision surgery [1]. With this approach, local
recurrence rates have fallen from 30 to 45% to < 10%.
Nevertheless, responses to treatment remain heteroge-
neous with up to 14% responding completely, 20% with
little or no regression and the remainder displaying a
spectrum between these two extremes [2]. Higher re-
sponse rates are associated with improved outcomes [3]
and innovative combinations with standard of care radi-
ation are an area of intense interest [4, 5]. In particular,
combining radiotherapy with immunotherapy is emerging
as a further opportunity to improve therapeutic results
and is a seen as a priority for research. Using a novel
oncolytic adenovirus, Enadenotucirev (EnAd), we aim to
elicit these benefits in rectal cancer.
Oncolytic viruses are novel anticancer agents that tar-
get, selectively replicate in, and kill cancer cells, spread-
ing through the tumour microenvironment, generating
local and systemic immune response both to themselves
as well as the dying tumour. One principal advantage of
oncolytic therapy is that the drug (the virus) replicates
only in malignant cells meaning that the concentration
of drug is amplified at the site of pathology so that it is
higher in the tumour than in healthy tissue; completely
different to standard drug pharmacokinetics. Virus parti-
cles can also spread from cell to cell within a tumour
nodule until they reach non-permissive normal tissues,
in principle targeting all viable tumour cells they
encounter [6, 7].
Rationale for the trial
There is a wealth of evidence to support the rationale
for combining this class of agent with radiation and has
recently been well reviewed [8]. Radiotherapy can modu-
late the expression of a large number of cellular genes
involved in cell cycle checkpoints, cellular stress, DNA
repair and apoptosis [9]. Adenoviruses have developed a
range of interactions with cellular DNA damage repair
proteins to allow successful viral replication. This has
implications for the initiation of a number of DNA re-
pair pathways activated in response to radiation-induced
damage, in particular, all adenoviral serotypes appear to
target Non Homologous End Joining (NHEJ) repair [10].
The hypothesis that oncolytic adenovirus infection
would work synergistically with radiotherapy has been
tested by a number of groups. The combination of
CG7870 adenovirus with radiation resulted in a synergis-
tic increase in cell killing, both in-vitro and in-vivo in
the LNCaP xenograft model, than either agent alone
[11]. Three Ad5-based vectors combined with radiation
have been studied in A549 lung cancer cells [12]. In-vivo
and in-vitro tumour cell kill was increased with the com-
bination approach. Similar findings have been noted
with a variety of different adenoviral vectors in other cell
types including ovarian cancer cell lines [13] and glioma
xenografts [14]. Importantly the effect of radiosensitiza-
tion does not appear to extend to normal tissues. The
combination of Ad5/CMV/p53 synergistically radiosensi-
tized two non-small cell lung cancer cell lines (A549 and
H322) in-vitro and in xenograft models, in a synergistic
fashion, but showed no increased radiosensitization ef-
fect on normal lung fibroblasts [15].
Clinical experience with virus/radiation combinations
has been limited to local (most commonly intratu-
moural) administration. This mode of delivery facilitates
direct infection ensuring correct dosing and avoids rapid
hepatic uptake seen with systemic delivery [16]. The
drawback was only tumour types that can be accessed
with a needle, such as skin, head and neck cancers, pros-
tate cancers, were considered suitable for clinical trials.
Nevertheless, the results of these studies provide useful
mechanistic indications as well as guiding assessment of
toxicity. Early phase evidence supports the hypothesis
that oncolytic adenovirus’ act to enhance radiation dam-
age across a range of tumour types including prostate
[17–20], head and neck SCC [21], pancreas [22], lung
[23] and CNS [24], with largely acceptable side effects
and toxicity profile [19, 25–28].
Enadenotucirev
Enadenotucirev is a group B oncolytic adenovirus under
development for the systemic treatment of metastatic or
advanced epithelial tumours. A chimeric adenovirus type
11p (Ad11p)/adenovirus type 3 (Ad3) virus, it was devel-
oped through a process of bio-selection where pools of
adenovirus serotypes are passaged on human tumor cell
lines to invite recombination of potent serotypes, in a
non-prejudicial way. Thus the human tumor directs the
evolution of select, highly potent adenovirus serotypes.
EnAd was derived from a pool of seven different adeno-
viruses serotypes utilizing human HT-29 colorectal can-
cer (CRC) cells [29]. As a consequence of this process,
EnAd shows selective and potent toxicity in human car-
cinoma cells with limited toxicity to normal (non-can-
cerous) human cells. Other than humans, there is no
known permissive species for EnAd.
While the overall understanding of the mechanism of
action of EnAd in humans is evolving, it is well estab-
lished from both non-clinical and clinical studies that
the mechanism of anti-cancer efficacy of oncolytic vi-
ruses elicit two primary effects; direct infection and lysis
of tumour cells and stimulated immune responses via
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increased release of tumour-associated antigens and
immune-inflammatory activation signals. The direct
oncolytic efficacy of EnAd has been demonstrated in a
number of non-clinical studies with human tumour cells
in-vitro and in-vivo [29, 30]. Replication of the enadeno-
tucirev virus in carcinoma cells resulted in direct necro-
lytic killing of carcinoma cells by a non-apoptotic,
immunogenic cell death mechanism which would be ex-
pected to trigger immune cells.
Two clinical studies of enadenotucirev given as a
monotherapy are important. The mechanism of action
study (ColoAd1–1002) established that intravenous de-
livery of EnAd was as efficient as intratumoral delivery
in colorectal cancer [31], making EnAd unique. The
EVOLVE (Evaluating Oncolytic Vaccine Efficacy) study
was a dose escalation and dosing schedule evaluation in
metastatic epithelial solid tumours which has established
the monotherapy maximum tolerated dose (MTD) [32].
Common adverse events associated with EnAd include
asthenia, flu like symptoms, nausea, vomiting,, pyrexia
and fatigue.
Aims of the trial
Our hypothesis is that enadenotucirev will, selectively,
downregulate DNA repair pathways in rectal cancer
cells, making them more susceptible to DNA damage
already incurred. Enadenotucirev also has the potential
to induce an immunogenic cell death in malignant cells
adding a complimentary, cytotoxic mechanism of action.
Enadenotucirev would address the combined require-
ments as therapy could act as both a local sensitizer
(DDR inhibitor/ direct tumour kill) and systemic (im-
mune response) agent. The aim of the trial is to find the
treatment schedule that has the optimal response-
toxicity trade-off, with no more than 30% probability of
a DLT. This is based on a historical G3+ adverse event
rate for CRT of approximately 30% [33, 34]. Modern
radiotherapy techniques means toxicity is expected to be
lower from CRT and recent studies with novel radiosen-
sitizers such as oxaliplatin reported G3/G4 toxicity in
the order of 25% [2].
Design/methods
CEDAR is a dual endpoint, dose escalation phase I trial
using a time to event continual reassessment method
(TiTE CRM). Response and toxicity endpoints will be
combined in dose escalation models to identify the opti-
mal dose schedule. We will recruit a maximum of 30 pa-
tients. Four centres will recruit to the study. Dose
escalation will be achieved by first increasing the fre-
quency of administration of EnAd followed by increasing
the viral particle dose of EnAd as detailed in the trial
flow chart (Fig. 1). These dose schedules are considered
ordered with increasing toxicity expected from one dose
schedule to the next.
Fig. 1 Overview of the study schema indicating timelines and interventions. [Blue = standard of care interventions; Green = viral particle
administrations; Red = investigational blood sample retrieval]
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Objectives
To determine the optimal dose and frequency of enade-
notucirev that can be administered with chemoradiation
for rectal cancer.
Primary Endpoints
 Dose limiting toxicity
 MRI tumour regression grade
Secondary Endpoints
 Ability to deliver enadenotucirev concurrently with
chemoradiation
 Assessment of treatment tolerance as measured
by the proportion of patients completing at least
80% of the intended Capecitabine dose and at
least 20 fractions of radiotherapy by the end of
week 9
 To measure local response rate to combined therapy
compared to pre-treatment status
 Pathological complete response rate
 Neoadjuvant rectal (NAR) score [35]
Exploratory Endpoints
 To identify ‘proof of concept’ that enadenotucirev
replicates in the tumour during chemoradiotherapy
 IHC staining of hexon protein coat in tumour




A patient will be eligible for inclusion in this trial if all
of the following criteria apply.
 Histologically confirmed invasive adenocarcinoma of
the rectum.
 Locally advance colorectal cancer as defined by
pelvic MRI with a threatened circumferential
resection margin (cT3mrf + ve), or inclusion of an
adjacent organ, or low tumours at/below the level of
the levators or enlarged pelvic side wall nodes or
selected by the multidisciplinary team MDT for
treatment with neoadjuvant (chemo)radiotherapy,
regardless of TNM classification
 Patients with oligometastatic disease suitable for radical
treatment are permitted provided that the site specific
MDT deems them suitable for chemoradiation
 Male or female, Age ≥ 18 years.
 ECOG performance score of 0–1
 The patient is willing and able to comply with the
protocol scheduled biopsy, follow-up visits and ex-
aminations for the duration of the trial.
 Written (signed and dated) informed consent.
 Adequate renal function demonstrated by:
 Creatinine ≤1.5 mg/dL and estimated glomerular
filtration rate (eGFR) ≥60 mL/min/1.73 m2 (or
measured creatinine clearance ≥60 mL/min)
 Urine dipstick for proteinuria at screening and
baseline negative or trace. Patients may be
included with results of 1+ if they have a spot
urinary albumin creatinine ratio (ACR) of either:
 ≤3 mg/mmol or
 > 3mg- < 70 mg/mmol with a 24 h urinary
protein < 0.2 g/24 h and
 Serum complement components C3 and C4
within the normal range
Exclusion criteria
 Pregnant or breast-feeding women, or women of
childbearing potential unless effective methods of
contraception are used.
 Past medical history:
 Known history or evidence of significant
immunodeficiency due to underlying illness and/
or medication (e.g. systemic corticosteroids, or
other immunosuppressive medications including
cyclosporine, azathioprine, interferons in the 4
weeks before the first dose of trial treatment)
 Splenectomy
 Prior allogeneic or autologous bone marrow or
organ transplantation
 Patients with a history of, or active, known or
suspected auto-immune disease or a syndrome
that requires systemic or immunosuppressive
agents; patients with vitiligo, type I diabetes melli-
tus, residual hypothyroidism due to autoimmune
disease only requiring hormone replacement,
psoriasis not requiring systemic treatment or
conditions not expected to recur in the absence
of an external trigger are permitted to enrol
 History of idiopathic pulmonary fibrosis, drug-
induced pneumonitis, or evidence of active
pneumonia or pneumonitis on computed tom-
ography scan
 Active viral disease or known positive serology
for HIV, hepatitis B or hepatitis C
 Active infections requiring antibiotics, physician
monitoring, or recurrent fevers > 38.0 °C
associated with a clinical diagnosis of active
infection
 Prior pelvic radiotherapy
 Any other active malignancy, with the
exception of adequately treated cone-biopsied
in situ carcinoma of the cervix uteri and non-
melanoma skin lesions.
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 Uncontrolled cardiorespiratory comorbidity (e.g.
inadequately controlled angina or myocardial
infarction in the last 6 months)
 Major disturbance in bowel function (e.g. severe
incontinence, Crohn’s disease, > 6 loperamide/
day)
 Use of the following antiviral agents: ribavirin,
adefovir, lamivudine or cidofovir within 7 days prior
to the first dose of trial treatment; or pegylated
interferon in the 14 days before the first dose of trial
treatment
 Treatment with any other investigational agent, or
participation in another interventional clinical trial
within 28 days prior to enrolment. Observational
studies are allowed
 Warfarin that cannot be discontinued at least 7 days
prior to starting treatment
 Known dihydropyrimidine dehydrogenase (DPYD)
deficiency
 Prior chemotherapy is allowed as long as > 28 days
since the last administration and any toxicity has
resolved to NCI CTCAE grade 1 or less
 Other psychological, social or medical condition,
physical examination finding or a laboratory
abnormality that the Investigator considers would
make the patient a poor trial candidate or could
interfere with protocol compliance or the
interpretation of trial results.
Statistical design
The trial will use a Time-to-Event Continual Reassess-
ment Model-based (TiTE-CRM) approach using toxicity
and efficacy primary endpoints to recommend the dose
and treatment schedule for future patients. MRI regres-
sion was chosen as the primary response endpoint, as
opposed to a pathological metric, so that response could
be assessed in all patients of a small cohort even in cases
of organ preservation. In using response alongside tox-
icity to inform the selection of the best dose, the trial
does not assume that an increase in dose causes an in-
crease in efficacy. This means that if the dose with the
best response rate is below the maximum tolerable dose
then it may be selected as the optimal dose. It also
means that marginal gains in efficacy which do not jus-
tify large increases in toxicity can be avoided. The
models for the two endpoints are Bayesian logistic
models with weakly informative priors calibrated to en-
sure the model provides sensible recommendations dur-
ing the early part of the study. Both models will use all
available information for every dose decision [36, 37].
Patients who have not reached the efficacy time point
yet will not provide any information to the model. Pa-
tients who have reached this time point but did not have
the evaluation, withdrew or died prior to evaluation will
be treated as non-responders. A further restriction on
escalation is that we will only escalate to an untried dose
if at least 2 patients have been given the dose below and
followed for at least 8 weeks.
The first 2 patients have been recruited and followed
until the end of the DLT window. From now on patients
will be recruited continuously and toxicity and response
models will be fitted every time a new patient is regis-
tered to decide which dose they will receive. We used
simulations to justify a sample size of 30.
Approvals
The trial is sponsored by the University of Oxford and was
approved by the South Central - Oxford B Research Ethics
Committee (REC Reference: 18/SC/0583). The study is part
funded by Cancer Research UK, PsiOxus Therapeutics and
adopted into the CT-RAD/NCRI portfolio.
Interventions
Chemoradiotherapy
Patients registered for the trial will receive standard che-
moradiation treatment which consists of Capecitabine
900 mg/m2 orally twice a day in equal doses (Mon-Fri)
on the days of radiotherapy for 25 daily treatments [38].
The radiotherapy protocol mandates the use of intraven-
ous contrast CT simulation with minimum 3mm CT
slices. Patients are immobilised supine with customised
pelvic immobilization equipment, with a comfortably full
bladder. 50Gy in 25 fractions will be delivered to the pri-
mary tumour (GTVp) and macroscopically involved
lymph nodes (GTVn), as a simultaneous integrated
boost, and 45Gy in 25 fractions to the pelvis/mesorectal
nodes and elective pelvic lymph nodes at risk (CTV),
prescribed according to recommendations by the Inter-
national Commission on Radiation Units and Measure-
ments (ICRU-50/62), to be delivered Monday to Friday
as an intensity modulated radiotherapy planned single-
phase treatment. An adapted atlas is provided to aid
with radiotherapy planning each case is reviewed to en-
sure consistency of radiotherapy delineation and radio-
therapy dose delivery. Patients are reviewed weekly
during RT (as per standard of care) and prior to each
administration of enadenotucirev.
Enadenotucirev
All participants will receive 3 x loading doses intraven-
ously in weeks 1–2, prior to initiation of chemoradiother-
apy. Loading doses, and maintenance doses if assigned,
should be given on 3 non-consecutive days over a 7-day
period (e.g. Mon/Wed/Fri or Fri/Mon/Wed or other con-
venient schedule). Further doses of enadenotucirev after
the 3 loading doses are dependent on the dose schedule
assigned, as per Table 1. As premedication, all patients
will receive 100mg IV hydrocortisone and 1 g oral
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paracetamol one hour prior to EnAd and again three
hours after EnAd.
Biopsy on treatment
The trial mandates a biopsy in the second week of CRT as
this forms the translational backbone of the study. IHC
staining of the specimen will provide ‘proof of concept’
that EnAd is present in the tumour. Additional specimens
will be fresh frozen for whole genome RNA sequencing
focused on DNA damage repair pathways and immune
signalling to understand mechanistic effects.
Dose limiting toxicity (DLT)
All patients who have received at least one dose of ena-
denotucirev will be evaluable for DLTs and are defined
as any of the following occurring between the start of
trial treatment until the Week 13 visit and by the princi-
pal investigator (PI) assessed as possibly, probably or
definitely related to enadenotucirev or the interaction
between enadenotucirev and radiotherapy and/or cape-
citabine. DLTs must be reported centrally within 24 h of
the site becoming aware.
Discussion
Attempts to improve standard of care radiotherapy for
rectal cancer have failed. Additional chemotherapy, such
as oxaliplatin or irinotecan, have not meaningfully im-
proved outcomes to date, whilst concurrent biologic
therapies (vascular endothelial growth factor (VEGF),
epidermal growth factor receptor (EGFR), Poly(ADP-ri-
bose) polymerase (PARP) inhibitors, etc.) have shown
promising results at the expense of increased toxicity
[39]. The reasons for failure are not purely biological
however. A recent review of Phase 2 trials in rectal
radiotherapy identified a number of issues including
poor trial design, heterogeneous patient groups, lack of a
validated efficacy endpoint as well as selection and
reporting bias [40].
There is a logical case for the additive, or even syner-
gistic, effect of oncolytic adenoviruses in combination
with radiotherapy. The novelty in this trial is that, for
the first time, we will be able to administer an oncolytic
adenovirus systemically knowing it has very high select-
ivity for colorectal cells and negligible ability to infect
normal tissues resulting in a very high hypothetical
therapeutic index. Furthermore, the issues of improved
radiosensitization in rectal cancer, mobilising an im-
mune response and targeting micrometastatic disease
can all be explored in the parallel translational program.
It is uncommon to perform a phase I trial in a radically
treated population who will receive curative surgery. But
rectal cancer offers the unique ability to explore transla-
tional hypotheses because of the sequence in which
standard of care clinical treatments are delivered, an op-
portunity increasingly availed of [41]. Patient and public
involvement feedback has been very positive also.
CEDAR is methodologically novel and efficient by de-
sign as well as multicentre. Although it requires signifi-
cant statistical support and engagement, our model will
predict an optimal dose and schedule of administration
to balance toxicity and efficacy. This should improve a
subsequent Phase II study with preliminary estimates
with which to power the chosen endpoint. The NAR
score, a secondary endpoint, is a validated predictor of
both OS [35] and DFS [42]. Rapid readout following sur-
gery will allow for an early assessment of a very strong
response signal even if the traditional pathological
complete response remains at the expected 12–15%.
These factors will attempt to overcome the previously
described flaws which have hampered treatment intensi-
fication for rectal radiotherapy.
Two recent high profile consensus statements on
novel drug radiotherapy combinations [4, 5] highlighted
five key messages: 1) the potential of combinations to
improve outcomes, 2) importance of communication be-
tween industry, academia, regulatory agencies and pa-
tient advocates, 3) intelligent trial design, 4) validated
endpoints and 5) novel approaches including immune-
oncology combined with radiotherapy should be priori-
tised. CEDAR is a bold new paradigm in the treatment
Table 1 Dose levels used for dose escalation. Two separate viral particle doses are used with escalation achieved by increasing the




(3 doses given on 3
non-consecutive days
over a 7 day period)
Concurrent Maintenance (post CRT)
(3 doses given on 3
non-consecutive days
over a 7 day period)
Week 1 Day 1 CRT
(week 3 day 1)
Week 1 Day 5 CRT
(week 3 day 5)
1 (start level) 1 × 1012 vp
2 1 × 1012 vp 1 × 1012 vp
3 1 × 1012 vp 1 × 1012 vp 1 × 1012 vp 1 × 1012 vp
4 3 × 1012 vp
5 3 × 1012 vp 3 × 1012 vp
6 3 × 1012 vp 3 × 1012 vp 3 × 1012 vp 3 × 1012 vp
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of rectal cancer which addresses all of these key aims.
The design and embedded translational program of
work will hopefully result in rapid progress to wider
clinical study, whilst underpinning the heretofore
unanswered in-vivo mechanistic questions of enadeno-
tucirev in rectal cancer.
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